---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021235"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2022-08-05T23:59:59+00:00"
generated_at: "2026-06-24T03:20:28.505250+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q3 FY2022 revenue $56.1M (+60% YoY), raises FY guidance to $203M

## Summary
- Revenue $56.1M (+60% YoY from $35.0M); orders $59.7M (+53% YoY).
- Net loss $60.5M ($1.08/sh) vs $40.0M ($0.82/sh) in prior year.
- Cash, cash equivalents and investments total $527.6M as of June 30, 2022.
- FY2022 revenue guidance raised to $203M from prior outlook.
- Launched Twist MRD Rapid 500 Panel, human monkeypox controls, and expanded EUA for SARS-CoV-2 NGS assay.

## SEC filing metadata
- accession: 0001628280-22-021235
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2022-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828022021235/0001628280-22-021235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828022021235/twist-20220805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021235
- JSON: https://secwatch.observer/filing/0001628280-22-021235.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.